Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Psychiatry Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Psychiatry Other
    Asenapine, Olanzapine Effective in Patients With Bipolar 1 Disorder: Presented at WCBP - (DGDispatch)
    FDA: Boxed Warning Required for Varenicline, Buproprion Due to Risk of Suicidal Behaviour - (DGNews)
    Quetiapine Monotherapy Shows Potential in Post-Traumatic Stress Disorder: Presented at WCBP - (DGDispatch)
    Olanzapine Effective for Bipolar Disorder in Naturalistic Setting: Presented at WCBP - (DGDispatch)
    Study Suggests Irritability Should Be Considered When Diagnosing Bipolar Disorder in Children - (DGNews)

    News archive

     Recent webcasts/CME - Psychiatry Other
      A Guide to Advances in Pain Management: A Synopsis of Roundtable Discussions
      Recognizing and Managing Psychotic and Mood Disorders in Primary Care
      Challenges of the Comorbid Patient: Evaluating Common Comorbidities in Adults and Children/Adolescents and Treatment Considerations
      Mixed States: Practical Application of Evidence, Guidelines, and Clinical Judgment
      Hypomania: The Clinical Reality of Diagnosing Adult and Child/Adolescent Patients

      Webcasts/CME archive

       Recent cases - Psychiatry Other
        Female Sexual Dysfunction as a Comorbid Illness
        11p Microdeletion Including WT1 but not PAX6, Presenting with Cataract, Mental Retardation, Genital Abnormalities and Seizures: Case Report
        Comorbidity of Asperger's Syndrome and Bipolar Disorder
        Psychiatric Disorder Associated with Vacuum-Assisted Breast Biopsy Clip Placement: A Case Report
        Treating Bipolar Disorder in Patients with Renal Failure Having Haemodialysis: Two Case Reports

        Cases archive
          




        my personal edition > psychiatry other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Vascular Dementia Patients Benefit From Donepezil Treatment: Presented at APA

        By Paula Moyer

        SAN FRANCISCO, CA -- May 26, 2003 -- People with vascular dementia appear to benefit from a cholinesterase inhibitor such as donepezil (Aricept) in much the same way that people with Alzheimer's disease do, according to findings presented here May 22nd at the 2003 Annual Meeting of the American Psychiatric Association.

        However, say researchers, treatment for vascular dementia seems to be associated with improvement rather than with a slowing of the disease's progression.

        Stephen P. Salloway, MD, and colleagues presented the results of the trials. Dr. Salloway, director of the Memory Disorders Program at Butler Hospital and an associate professor of clinical neuroscience at Brown Medical Center in Providence, Rhode Island, United States, attributed this treatment effect to the difference in the natural course in the 2 dementia subtypes and noted that vascular dementia is characterized by long periods of stabilization.

        "These are the first large-scale placebo-controlled trials of an acetylcholinesterase inhibitor that have focused on people with possible or probable vascular dementia," he said.

        Because there are currently no approved treatments for the cognitive symptoms of vascular dementia, and because prior research had suggested that such patients may benefit from treatment with cholinesterase inhibitors such as donepezil, the investigators conducted a combined analysis of 2 randomized, 24-week clinical trials of donepezil in 1,219 patients with probable or possible vascular dementia.

        The criteria used to determine probable or possible vascular dementia were those that had been jointly established by the National Institute for Neurologic Disease and Stroke (NINDS) and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences (AIREN). They are therefore known as the NINDS-AIREN criteria

        Patients received donepezil 5 mg/day (406 patients), donepezil 10 mg/day (421 patients), or placebo (392 patients). The 10-mg group received 5 mg daily for the first 28 days and 10 mg daily for the rest of the study period.

        Both treated groups showed significant improvements in cognitive function compared with the placebo group, as measured by the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog). By week 24, the placebo group had a mean score change of -0,10, compared with a mean change of -1.89 in the 5-mg group and -2.38 in the 10-mg group (P<0.001 for each).

        The investigators also documented significant benefits to treatment over placebo in global function. By week 24, 29% of the placebo patients had improved scores on the Clinician's Interview-Based Impression of Change, compared with 41% of the 5-mg group (P<0.001) and 33% of the 10-mg group (P=0.07)(P=0.001 overall). The treated patients also showed improvements on the Clinical Dementia Rating-Sum of the Boxes scores (CDR-SB).

        By week 24, the placebo patients' mean CDR-SB score had increased by 0.10, while the 5-mg group's mean score had decreased by 0.11, and the 10-mg group's mean score had decreased by 0.33, (P=0.001 and P=0.002, respectively).

        "One question one could ask is, 'Are we just treating an Alzheimer's disease population that has had cerebrovascular changes?'" Dr. Salloway said. "However, these patients differed in significant ways from typical Alzheimer's disease patients. Most were men, they were older than patients typically are in Alzheimer's disease trials, and they had higher Mini-Mental Status Exam scores. The imaging studies also showed more cerebrovascular disease than is typically seen in Alzheimer's disease."

        These results show that donepezil may have potential for managing vascular dementia, he said.

        The trials were sponsored by Eisai, Inc.


        [Study title: Donepezil Provides Significant Benefits In Patients With Vascular Dementia. Abstract NR882]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send